Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Managing Cancer Treatment in Patients with Renal Dysfunction: The Role of Chemotherapy

Author(s): Ziba Aghsaeifard and Reza Alizadeh*

Volume 23, Issue 16, 2023

Published on: 19 July, 2023

Page: [1811 - 1818] Pages: 8

DOI: 10.2174/1871520623666230602143525

Price: $65

Abstract

Malignancy is characterized by damage to several vital organs, and utilizing chemotherapy as a treatment option can have toxic effects on healthy body tissues. Kidney function is commonly compromised by cancer and chemotherapy. These effects can be pre-renal, intrarenal, or postrenal. Tumor lysis syndrome and electrolyte disturbances are also common in this group of patients. Etiologies of this dysfunction are poorly understood; therefore, careful monitoring and management of renal function are required in such cases. This narrative review aimed to highlight some of the common renal abnormalities among patients receiving cancer and chemotherapy.

« Previous Next »
[1]
Aghsaeifard, Z.; Ghafarzadeh, M.; Alizadeh, R. Pregnancy and sex hormone changes after kidney transplant. Clin. Invest. Ginecol. Obstet., 2023, 50(1), 100812.
[http://dx.doi.org/10.1016/j.gine.2022.100812]
[2]
Canet, E.; Zafrani, L.; Lambert, J.; Thieblemont, C.; Galicier, L.; Schnell, D.; Raffoux, E.; Lengline, E.; Chevret, S.; Darmon, M.; Azoulay, E. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One, 2013, 8(2), e55870.
[http://dx.doi.org/10.1371/journal.pone.0055870] [PMID: 23457485]
[3]
Alizadeh, R.; Aghsaeifard, Z. Two-way road of kidney and hypercalcemia: A narrative review. Cardiovasc. Hematol. Disord. Drug Targets, 2022, 22(4), 200-206.
[http://dx.doi.org/10.2174/1871529X23666221205143041] [PMID: 36475333]
[4]
Rosner, M.H.; Perazella, M.A. Acute kidney injury in patients with cancer. N. Engl. J. Med., 2017, 376(18), 1770-1781.https://www.nejm.org/doi/full/10.1056/NEJMra1613984
[http://dx.doi.org/10.1056/NEJMra1613984] [PMID: 28467867]
[5]
Aghsaeifard, Z.; Alizadeh, R.; Bagheri, N. Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease. Arch. Physiol. Biochem., 2022, 128(3), 703-707.
[http://dx.doi.org/10.1080/13813455.2020.1720742] [PMID: 31994917]
[6]
Miao, J.; Sise, M.E.; Herrmann, S.M. Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. Front. Neurol., 2022, 2, 1017921.
[http://dx.doi.org/10.3389/fneph.2022.1017921]
[7]
Alizadeh, R.; Aghsaeifard, Z. Clinical post-transplant lymphoproliferative disorders. Cardiovasc. Hematol. Disord. Drug Targets, 2022, 22(2), 96-103.
[http://dx.doi.org/10.2174/1871529X22666220804155810]
[8]
Santos, M.L.C.; Brito, B.B.; Silva, F.A.F.; Botelho, A.C.S.; Melo, F.F. Nephrotoxicity in cancer treatment: An overview. World J. Clin. Oncol., 2020, 11(4), 190-204.
[http://dx.doi.org/10.5306/wjco.v11.i4.190] [PMID: 32355641]
[9]
Małyszko, J.; Kozlowski, L.; Kozłowska, K.; Małyszko, M.; Małyszko, J. Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine? Oncotarget, 2017, 8(39), 66601-66619.
[http://dx.doi.org/10.18632/oncotarget.18094] [PMID: 29029541]
[10]
Amarapurkar, P.; Bou-Slaiman, S.; Madrid, B.; Ladino, M. Paraneoplastic glomerular disease: The struggle is real. J. Onco-Nephrol., 2019, 3(1), 31-38.
[http://dx.doi.org/10.1177/2399369319828732]
[11]
Lefaucheur, C.; Stengel, B.; Nochy, D.; Martel, P.; Hill, G.S.; Jacquot, C.; Rossert, J. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int., 2006, 70(8), 1510-1517.
[http://dx.doi.org/10.1038/sj.ki.5001790] [PMID: 16941021]
[12]
Jhaveri, K.D.; Shah, H.H.; Calderon, K.; Campenot, E.S.; Radhakrishnan, J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int., 2013, 84(1), 34-44.
[http://dx.doi.org/10.1038/ki.2012.484] [PMID: 23364518]
[13]
Aghsaeifard, Z.; Alizadeh, R. Drug-induced interstitial nephritis as a result of sodium valproate and triamterene. Urol. Case Rep., 2020, 33, 101329.
[http://dx.doi.org/10.1016/j.eucr.2020.101329] [PMID: 33102031]
[14]
Beck, L.H., Jr PLA2R and THSD7A: Disparate paths to the same disease? J. Am. Soc. Nephrol., 2017, 28(9), 2579-2589.
[http://dx.doi.org/10.1681/ASN.2017020178] [PMID: 28674044]
[15]
Küppers, R.; Schwering, I.; Bräuninger, A.; Rajewsky, K.; Hansmann, M.L. Biology of Hodgkin’s lymphoma. Ann. Oncol., 2002, 13(Suppl. 1), 11-18.
[http://dx.doi.org/10.1093/annonc/13.S1.11] [PMID: 12078890]
[16]
Cambier, Jean-François; Ronco, Pierre Onco-nephrology: Glomerular diseases with cancer. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1701-1712.
[http://dx.doi.org/10.2215/CJN.03770412]
[17]
Ronco, P.; Plaisier, E. Immunoglobulin light (heavy)-chain deposition disease: From molecular medicine to pathophysiology-driven therapy. Clin. J. Amer. Soc. Nephrol., 2006, 1(6), 1342-1350.
[http://dx.doi.org/10.2215/CJN.01730506]
[18]
Gnemmi, V.; Leleu, X.; Provot, F.; Moulonguet, F.; Buob, D. Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia. Am. J. Kidney Dis., 2012, 60(3), 487-491.
[http://dx.doi.org/10.1053/j.ajkd.2012.01.030] [PMID: 22721930]
[19]
Toriu, N.; Sawa, N.; Imafuku, A.; Hasegawa, E.; Sekine, A.; Mizuno, H.; Yamanouchi, M.; Hiramatsu, R.; Hayami, N.; Hoshino, J.; Kawada, M.; Suwabe, T.; Ohashi, K.; Fujii, T.; Ubara, Y. Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. CEN Case Rep., 2020, 9(4), 347-353.
[http://dx.doi.org/10.1007/s13730-020-00485-7] [PMID: 32378178]
[20]
Heo, M.H.; Kim, H.K.; Lee, H.; Ahn, M.J. Antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis after pembrolizumab treatment in thymic epithelial tumor: A case report. J. Thorac. Oncol., 2017, 12(8), e103-e105.
[http://dx.doi.org/10.1016/j.jtho.2017.03.011] [PMID: 28342816]
[21]
Wu, S.; Dahut, W.L.; Gulley, J.L. The use of bisphosphonates in cancer patients. Acta Oncol., 2007, 46(5), 581-591.
[http://dx.doi.org/10.1080/02841860701233435] [PMID: 17562434]
[22]
Jia, N.; Cormack, F.C.; Xie, B.; Shiue, Z.; Najafian, B.; Gralow, J.R. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC Cancer, 2015, 15(1), 535.
[http://dx.doi.org/10.1186/s12885-015-1536-y] [PMID: 26197890]
[23]
Miller, P.D. The kidney and bisphosphonates. Bone, 2011, 49(1), 77-81.
[http://dx.doi.org/10.1016/j.bone.2010.12.024] [PMID: 21232648]
[24]
Oberic, L.; Buffet, M.; Schwarzinger, M.; Veyradier, A.; Clabault, K.; Malot, S.; Schleinitz, N.; Valla, D.; Galicier, L.; Bengrine-Lefèvre, L.; Gorin, N.C.; Coppo, P. Cancer awareness in atypical thrombotic microangiopathies. Oncologist, 2009, 14(8), 769-779.
[http://dx.doi.org/10.1634/theoncologist.2009-0067] [PMID: 19684072]
[25]
Mielczarek, Ł. Brodziak, A.; Sobczuk, P.; Kawecki, M.; Cudnoch-Jędrzejewska, A.; Czarnecka, A.M. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer Chemother. Pharmacol., 2021, 87(6), 723-742.
[http://dx.doi.org/10.1007/s00280-021-04260-y] [PMID: 33768301]
[26]
Al-Nouri, Z.L.; Reese, J.A.; Terrell, D.R.; Vesely, S.K.; George, J.N. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125(4), 616-618.
[http://dx.doi.org/10.1182/blood-2014-11-611335] [PMID: 25414441]
[27]
Lien, Y.H.H.; Lai, L.W. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat. Rev. Nephrol., 2011, 7(2), 85-95.
[http://dx.doi.org/10.1038/nrneph.2010.171] [PMID: 21151207]
[28]
Hausberg, M.; Felten, H.; Pfeffer, S. Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer. Case Rep. Oncol., 2019, 12(1), 1-6.
[http://dx.doi.org/10.1159/000495031] [PMID: 30792638]
[29]
Kapiteijn, E.; Brand, A.; Kroep, J.; Gelderblom, H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol., 2007, 18(10), 1745-1747.
[http://dx.doi.org/10.1093/annonc/mdm454] [PMID: 17890216]
[30]
Morton, J.M.; George, J.N. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J. Oncol. Pract., 2016, 12(6), 523-530.https://ascopubs.org/doi/full/10.1200/jop.2016.012096
[http://dx.doi.org/10.1200/JOP.2016.012096] [PMID: 27288467]
[31]
Winters, J.L. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematology (Am. Soc. Hematol. Educ. Program), 2017, 2017(1), 632-638.
[http://dx.doi.org/10.1182/asheducation-2017.1.632] [PMID: 29222314]
[32]
Lam, A.Q.; Humphreys, B.D. Onco-Nephrology. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1692-1700.
[http://dx.doi.org/10.2215/CJN.03140312] [PMID: 22879433]
[33]
Campbell, G.A.; Hu, D.; Okusa, M.D. Acute kidney injury in the cancer patient. Adv. Chronic Kidney Dis., 2014, 21(1), 64-71.
[http://dx.doi.org/10.1053/j.ackd.2013.08.002] [PMID: 24359988]
[34]
Okada, H.; Kikuta, T.; Kobayashi, T.; Inoue, T.; Kanno, Y. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J. Amer. Soc. Nephrol., 2005, 16(1), 133-143.
[http://dx.doi.org/10.1681/ASN.2004040339]
[35]
Aghsaeifard, Z.; Latifi, M.; Bagherpour, F.; Rahbar, M.; Rahimzadeh, H.; Namdari, F.; Dialameh, H.; Taheri Mahmoudi, M.; Dehghani, S. Choriocarcinoma transmitted with the transplant: Case study. SAGE Open Med. Case Rep., 2022, 10, 2050313X2210875.
[http://dx.doi.org/10.1177/2050313X221087567] [PMID: 35449531]
[36]
Vaglio, A.; Maritati, F. Idiopathic retroperitoneal fibrosis. J. Am. Soc. Nephrol., 2016, 27(7), 1880-1889.
[http://dx.doi.org/10.1681/ASN.2015101110] [PMID: 26860343]
[37]
Surcel, C.; Mirvald, C.; Pavelescu, C.; Gingu, C.; Carmen, S.; Emre, H.; Ioanel, S. Management of idiopathic retroperitoneal fibrosis from the urologist’s perspective. Ther. Adv. Urol., 2015, 7(2), 85-99.
[http://dx.doi.org/10.1177/1756287214565637]
[38]
Ingles Garces, A.H.; Ang, J.E.; Ameratunga, M.; Chénard-Poirier, M.; Dolling, D.; Diamantis, N.; Seeramreddi, S.; Sundar, R.; de Bono, J.; Lopez, J.; Banerji, U. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. Eur. J. Cancer, 2018, 104(104), 32-38.
[http://dx.doi.org/10.1016/j.ejca.2018.08.019] [PMID: 30316017]
[39]
Gupta, R.; Matthew, N.J. Hypercalcemia due to vitamin D-secreting hodgkin’s lymphoma exacerbated by oral calcium supplementation. Endocrine Practice, 12(2), 227-229.
[http://dx.doi.org/10.4158/EP.12.2.227]
[40]
Berardi, R.; Rinaldi, S.; Caramanti, M.; Grohè, C.; Santoni, M.; Morgese, F.; Torniai, M.; Savini, A.; Fiordoliva, I.; Cascinu, S. Hyponatremia in cancer patients: Time for a new approach. Crit. Rev. Oncol. Hematol., 2016, 102, 15-25.
[http://dx.doi.org/10.1016/j.critrevonc.2016.03.010] [PMID: 27066939]
[41]
Onitilo, A.A.; Kio, E.; Doi, S.A.R. Tumor-related hyponatremia. Clin. Med. Res., 2007, 5(4), 228-237.
[http://dx.doi.org/10.3121/cmr.2007.762] [PMID: 18086907]
[42]
Mentrasti, G.; Scortichini, L.; Torniai, M.; Giampieri, R.; Morgese, F.; Rinaldi, S.; Berardi, R. Syndrome of inappropriate antidiuretic hormone secretion (SIADH): Optimal management. Ther. Clin. Risk Manag., 2020, 16, 663-672.
[http://dx.doi.org/10.2147/TCRM.S206066] [PMID: 32801723]
[43]
Verzicco, I.; Regolisti, G.; Quaini, F.; Bocchi, P.; Brusasco, I.; Ferrari, M.; Passeri, G.; Cannone, V.; Coghi, P.; Fiaccadori, E.; Vignali, A.; Volpi, R.; Cabassi, A. Electrolyte disorders induced by antineoplastic drugs. Front. Oncol., 2020, 10, 779.
[http://dx.doi.org/10.3389/fonc.2020.00779] [PMID: 32509580]
[44]
Shirali, A. Electrolyte and acid-base disorders in malignancy.Onco-nephrology curriculum; American society of nephrology: Washington, DC, USA, 2016.
[45]
Rosner, M.H.; Perazella, M.A. Acute kidney injury in the patient with cancer. Kidney Res. Clin. Pract., 2019, 38(3), 295-308.
[http://dx.doi.org/10.23876/j.krcp.19.042] [PMID: 31284363]
[46]
Bowman, B.T. Electrolyte disorders associated with cancer. Journal of Onco-Nephrology, 2017, 1(1), 30-35.
[http://dx.doi.org/10.5301/jo-n.5000004]
[47]
Chaudhary, D.P.; Sharma, R.; Bansal, D.D. Implications of magnesium deficiency in type 2 diabetes: a review. Biol. Trace Elem. Res., 2010, 134(2), 119-129.
[http://dx.doi.org/10.1007/s12011-009-8465-z] [PMID: 19629403]
[48]
Lam, M.; Adelstein, D.J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am. J. Kidney Dis., 1986, 8(3), 164-169.
[http://dx.doi.org/10.1016/S0272-6386(86)80020-8] [PMID: 3752072]
[49]
Rude, R.K. Magnesium deficiency: a cause of heterogeneous disease in humans. J. Bone Miner. Res., 1998, 13(4), 749-758.
[http://dx.doi.org/10.1359/jbmr.1998.13.4.749] [PMID: 9556074]
[50]
Dreizen, S.; McCredie, K.B.; Keating, M.J.; Andersson, B.S. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad. Med., 1990, 87(1), 163-170, 170.
[http://dx.doi.org/10.1080/00325481.1990.11704531] [PMID: 2296564]
[51]
Gupta, D.; Vashi, P.G.; Trukova, K.; Lis, C.G.; Lammersfeld, C.A. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp. Ther. Med., 2011, 2(2), 181-193.
[http://dx.doi.org/10.3892/etm.2011.205] [PMID: 22977487]
[52]
Pullar, J.; Carr, A.; Vissers, M. The roles of vitamin C in skin health. Nutrients, 2017, 9(8), 866.
[http://dx.doi.org/10.3390/nu9080866] [PMID: 28805671]
[53]
Darmon, M.; Vincent, F.; Camous, L.; Canet, E.; Bonmati, C.; Braun, T.; Caillot, D.; Cornillon, J.; Dimicoli, S.; Etienne, A.; Galicier, L.; Garnier, A.; Girault, S.; Hunault-Berger, M.; Marolleau, J.P.; Moreau, P.; Raffoux, E.; Recher, C.; Thiebaud, A.; Thieblemont, C.; Azoulay, E. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br. J. Haematol., 2013, 162(4), 489-497.
[http://dx.doi.org/10.1111/bjh.12415] [PMID: 23772757]
[54]
Sherwood, G.B.; Paschal, R.D.; Adamski, J. Rasburicase‐induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. Clin. Case Rep., 2016, 4(4), 315-319.
[http://dx.doi.org/10.1002/ccr3.495] [PMID: 27099716]
[55]
Mirrakhimov, A.E.; Ali, A.M.; Khan, M.; Barbaryan, A. Tumor lysis syndrome in solid tumors: An up to date review of the literature. Rare Tumors, 2014, 6(2), 68-76.
[http://dx.doi.org/10.4081/rt.2014.5389] [PMID: 25002953]
[56]
Abu-Alfa, A.K.; Younes, A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am. J. Kidney Dis., 2010, 55(5)(Suppl. 3), S1-S13.
[http://dx.doi.org/10.1053/j.ajkd.2009.10.056] [PMID: 20420966]
[57]
Reed, D.R.; Pierce, E.J.; Sen, J.M.; Keng, M.K. A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate. Cancer Manag. Res., 2019, 11, 8065-8072.
[http://dx.doi.org/10.2147/CMAR.S190084] [PMID: 31507329]
[58]
Chen, C.; Lü, J.M.; Yao, Q. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: An overview. Med. Sci. Monit., 2016, 22, 2501-2512.
[http://dx.doi.org/10.12659/MSM.899852] [PMID: 27423335]
[59]
Pession, A.; Melchionda, F.; Castellini, C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics, 2008, 2(1), 129-141.
[PMID: 19707436]
[60]
Chao, J.; Terkeltaub, R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr. Rheumatol. Rep., 2009, 11(2), 135-140.
[http://dx.doi.org/10.1007/s11926-009-0019-z] [PMID: 19296886]
[61]
Bessmertny, O.; Robitaille, L.; Cairo, M. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr. Pharm. Des., 2005, 11(32), 4177-4185.
[http://dx.doi.org/10.2174/138161205774913291] [PMID: 16375739]
[62]
Cairo, M.S.; Bishop, M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol., 2004, 127(1), 3-11.
[http://dx.doi.org/10.1111/j.1365-2141.2004.05094.x] [PMID: 15384972]
[63]
Vadhan-Raj, S.; Fayad, L.E.; Fanale, M.A.; Pro, B.; Rodriguez, A.; Hagemeister, F.B.; Bueso-Ramos, C.E.; Zhou, X.; McLaughlin, P.W.; Fowler, N.; Shah, J.; Orlowski, R.Z.; Samaniego, F.; Wang, M.; Cortes, J.E.; Younes, A.; Kwak, L.W.; Sarlis, N.J.; Romaguera, J.E. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann. Oncol., 2012, 23(6), 1640-1645.
[http://dx.doi.org/10.1093/annonc/mdr490] [PMID: 22015451]
[64]
Nakamura, M.; Oda, S.; Sadahiro, T.; Hirayama, Y.; Tateishi, Y.; Abe, R.; Hirasawa, H. The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus. Apheresis Sci., 2009, 40(1), 41-47.
[http://dx.doi.org/10.1016/j.transci.2008.11.004] [PMID: 19109071]
[65]
Lin, C.J.; Chen, H.H.; Hsieh, R.K.; Chen, Y.C.; Wu, C.J. Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma. Med. Oncol., 2009, 26(1), 93-95.
[http://dx.doi.org/10.1007/s12032-008-9064-0] [PMID: 18770053]
[66]
Humphreys; Benjamin, D. Soiffer, R.J.; Magee, C.C. Renal failure associated with cancer and its treatment: An update. J. Amer. Soc. Nephrol., 2005, 16(1), 151-161.
[http://dx.doi.org/10.1681/ASN.2004100843]
[67]
Wilson, F.P.; Berns, J.S. Tumor lysis syndrome: new challenges and recent advances. Adv. Chronic Kidney Dis., 2014, 21(1), 18-26.
[http://dx.doi.org/10.1053/j.ackd.2013.07.001] [PMID: 24359983]
[68]
Małyszko, J.; Kozłowska, K.; Kozłowski, L.; Małyszko, J. Nephrotoxicity of anticancer treatment. Nephrol. Dial. Transplant., 2016, 32(6), gfw338.
[http://dx.doi.org/10.1093/ndt/gfw338] [PMID: 28339935]
[69]
Jagieła, J.; Bartnicki, P.; Rysz, J. Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer. Int. J. Mol. Sci., 2021, 22(9), 4618.
[http://dx.doi.org/10.3390/ijms22094618] [PMID: 33924827]
[70]
Gupta, S.; Gudsoorkar, P.; Jhaveri, K.D. Acute kidney injury in critically Ill patients with cancer. Clin. J. Am. Soc. Nephrol., 2022, 17(9), 1385-1398.
[http://dx.doi.org/10.2215/CJN.15681221]
[71]
Chiruvella, V.; Annamaraju, P.; Guddati, A.K. Management of nephrotoxicity of chemotherapy and targeted agents. Am. J. Cancer Res., 2020, 10(12), 4151-4164.
[PMID: 33414992]
[72]
Lotfi, R.; Tehrani, F.R.; Dovom, M.R.; Torkestani, F.; Abedini, M.; Sajedinejad, S. Development of strategies to reduce cesarean delivery rates in iran 2012-2014: a mixed methods study. Int. J. Prev. Med., 2014, 5(12), 1552-1566.
[PMID: 25709791]
[73]
Li, H.; Xu, J.; Bai, Y.; Zhang, S.; Cheng, M.; Jin, J. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: A systematic review and meta-analysis. Invest. New Drugs, 2021, 39(3), 860-870.
[http://dx.doi.org/10.1007/s10637-020-01039-5] [PMID: 33409896]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy